ResMed (RMD) Misses Q3 EPS by 1c

ResMed (NYSE: RMD) reported Q3 EPS of $0.68, $0.01 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $453.9 million versus the consensus estimate of $455.88 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Twin Disc (TWIN) Tops Q4 EPS by 16c
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue